Least Anticholinergic Antiemetics for Chemotherapy-Induced and Postoperative Nausea and Vomiting

Introduction to Antiemetic Classes

The National Comprehensive Cancer Network recommends 5-HT3 receptor antagonists, NK1 receptor antagonists, and dexamethasone as the least anticholinergic antiemetics for effective control of nausea and vomiting in patients undergoing chemotherapy or surgery 1, 2

5-HT3 antagonists, including ondansetron, granisetron, and dolasetron, have minimal anticholinergic properties and are effective in preventing acute and delayed nausea and vomiting in patients undergoing chemotherapy or surgery 1, 2
These agents work by selectively blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract, rather than blocking muscarinic receptors, resulting in minimal anticholinergic effects 2

Aprepitant and fosaprepitant selectively block substance P at NK1 receptors in the central nervous system, providing a mechanism of action distinct from anticholinergic pathways and effective control of nausea and vomiting in patients undergoing chemotherapy or surgery 1, 2
NK1 receptor antagonists have minimal anticholinergic properties, with primary side effects being fatigue rather than anticholinergic symptoms, making them a suitable option for patients at risk of anticholinergic side effects 2

Dexamethasone works through anti-inflammatory mechanisms rather than anticholinergic pathways, making it an effective antiemetic with minimal anticholinergic properties for patients undergoing chemotherapy or surgery 1
The use of dexamethasone improves the efficacy of antiemetic regimens containing 5-HT3 antagonists without adding anticholinergic burden, according to the National Comprehensive Cancer Network guidelines 1

For patients at risk of anticholinergic side effects, combining antiemetics from different classes with minimal anticholinergic properties, such as 5-HT3 antagonists, NK1 receptor antagonists, and dexamethasone, maximizes efficacy while minimizing anticholinergic burden 1
A combination of palonosetron, dexamethasone, and aprepitant provides excellent control of chemotherapy-induced nausea and vomiting with minimal anticholinergic effects, as recommended by the National Comprehensive Cancer Network 1

The American Society of Clinical Oncology recommends palonosetron as the preferred 5-HT3 antagonist due to its superior efficacy in preventing both acute and delayed nausea and vomiting 3, 4
The National Comprehensive Cancer Network suggests dosing recommendations for 5-HT3 antagonists: ondansetron 8 mg oral twice daily or 8 mg/0.15 mg/kg IV, palonosetron 0.50 mg oral or 0.25 mg IV, and granisetron 2 mg oral or 1 mg/0.01 mg/kg IV 5
Dexamethasone 8 mg oral or IV is effective as a single agent for low emetogenic risk situations, and can be combined with 5-HT3 antagonists for enhanced efficacy in moderate to high emetogenic scenarios 5, 6

The American Society of Clinical Oncology recommends aprepitant (125 mg oral day 1, followed by 80 mg days 2-3) or fosaprepitant (150 mg IV day 1 only) for highly emetogenic chemotherapy, particularly in combination with 5-HT3 antagonists and dexamethasone 5, 7
Lorazepam (0.5-2.0 mg every 4-6 hours orally, IV, or sublingual) can be added to any antiemetic regimen, particularly for anxiety-related nausea or anticipatory nausea/vomiting 4, 8

For high emetogenic risk chemotherapy-induced nausea and vomiting, a three-drug combination of NK1 antagonist + 5-HT3 antagonist (preferably palonosetron) + dexamethasone is recommended 7
For moderate emetogenic risk, a two-drug combination of palonosetron + dexamethasone is suggested 6
For low emetogenic risk, a single 8 mg dose of dexamethasone is recommended 6

For pediatric patients receiving chemotherapy of high or moderate emetic risk, the combination of a 5-HT3 antagonist plus a corticosteroid is recommended, with higher weight-based doses of 5-HT3 antagonists than those used in adults 6